Format

Send to

Choose Destination
Cancer Invest. 2014 May;32(4):150-7. doi: 10.3109/07357907.2014.889706. Epub 2014 Mar 7.

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.

Author information

1
Department of Medicine, College of Physicians and Surgeons,1 Herbert Irving Comprehensive Cancer Center,2 Departments of Epidemiology and Biostatistics, Mailman School of Public Health,3 Department of Surgery, College of Physicians and Surgeons,4 Department of Medicine, Laboratory Irving Institute for Clinical and Translational Research, College of Physicians and Surgeons,5 Department of Pathology and Cell Biology,6 College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Abstract

INTRODUCTION:

We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.

METHODS:

Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.

RESULTS:

There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.

CONCLUSION:

Despite no proliferation changes, we observed reductions in other relevant biomarkers.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00930579.

PMID:
24605899
PMCID:
PMC4435671
DOI:
10.3109/07357907.2014.889706
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center